TABLE 3.

Concentrations of telithromycin in plasma, alveolar macrophages, and ELF of 23 healthy subjects after administration of telithromycin at 800 mg once daily for 5 days

Time (h) after last dose	Median (range) concn (mg/liter)			Median (range) ratio of the concn in the following to concn in plasma:
	AMa	ELFb	Plasmac	AM	ELF
2d(n = 5)	49 (16–168)	5.5 (0.7–11.7)	1.14 (0.53–1.85)	50 (30–91)	3.1 (1.1–10.3)
8e(n = 6)	81 (56–166)	3.7 (1.2–7.5)	0.63 (0.42–0.72)	146 (77–395)	6.4 (2.0–10.4)
24f(n = 6)	23 (10–142)	0.82h (0.15–3.22)	0.055 (0.03–0.15)	407 (165–1041)	12.7b (3.8–27.3)
48g(n = 6)	2.15i (1.95–2.35)	0.17j (0.17–0.55)	<0.03

^aFor pairwise comparisons of telithromycin concentrations in alveolar macrophages (AM), underlined data are not statistically significant (P > 0.05), and italic data are not statistically significant (P > 0.05). 

^bFor pairwise comparisons of telithromycin concentrations in ELF, underlined data are not statistically significant (P > 0.05), and italic data are not statistically significant (P > 0.05). 

^cFor pairwise comparisons of telithromycin concentrations in plasma, underlined data are not statistically significant (P > 0.05). 

^dWithin the 2-h group, telithromycin concentrations were as follows: alveolar macrophages > ELF > plasma (P < 0.05). 

^eWithin the 8-h group, telithromycin concentrations were as follows: alveolar macrophages > ELF > plasma (P < 0.05). 

^fWithin the 24-h group, telithromycin concentrations were as follows: alveolar macrophages > ELF > plasma (P < 0.05). 

^gWithin the 48-h group, telithromycin concentrations were as follows: alveolar macrophages > ELF > plasma (P < 0.05). 

^hn = 5. 

ⁱn = 2. 

^jn = 3.